Atul Arun Shirkhedkar
Research Subjects
Atul Arun Shirkhedkar has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Amod S. Patil
Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India
10 shared publications- Saurabh B. Ganorkar
R.C.Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, 425405, Maharashtra, India
7 shared publications - Sanjay Javerilal Surana
R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist. Dhule, 425405, Maharashtra, India
6 shared publications Suraj R. Chaudhari
Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India
6 shared publications- Suraj R. Chaudhari
Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India
5 shared publications - Akhil Nagar
R. C. Patel Institute of Pharmaceutical Education and Research
3 shared publications
Latest Publications
- 15 May 2026
- Published by Chitkara University Publications in Journal of Pharmaceutical Technology, Research and Management
- Vol. 13 (2) , 48-59
HPTLC Driven Analytical Approaches for Antidiabetic Pharmaceuticals: A Detailed Review
Background: Diabetes mellitus is a chronic disease affecting a large number of populations across the world, and it also requires management using anti-diabetic drugs. Various drugs such as metformin, vildagliptin, saxagliptin, sitagliptin, rosiglitazone, glipizide, and their combinations are commonly used for the treatment. Numerous pharmaceutical formulations are available in the market in combination forms as well. In order to ensure the quality, appropriate dosage, and regulatory compliance of these formulations, accurate and reliable analytical methods are essential. Purpose: This review will provide comprehensive insight into HPTLC-based analytical approaches used for qualitative and quantitative analysis of anti-diabetic drugs in various pharmaceutical formulations. Methods: This review critically summarizes the literature reporting HPTLC methods developed for the analysis of anti-diabetic drugs. Key aspects such as HPTLC method development, mobile phase and stationary phase selection, detection methods, and optimization strategies are discussed. Method validation parameters such as robustness, sensitivity, reproducibility, and accuracy are mentioned. Results: The study demonstrated that the HPTLC method is a reliable and efficient analytical technique for the evaluation of anti-diabetic drugs due to its low cost, high reproducibility, minimal solvent consumption, and ability to analyze multiple samples simultaneously. For routine quality control and research applications, validated HPTLC methods have shown satisfactory performance. Conclusion: HPTLC represents itself as a valuable tool for the qualitative as well as quantitative assessment of anti-diabetic formulations. This detailed review provides guidance for researchers as well as analysts in selecting and optimizing appropriate HPTLC protocols for research and quality control purposes. It also highlights the potential for further advancements in HPTLC-based drug analysis.
- 15 May 2026
- Published by Chitkara University Publications in Journal of Pharmaceutical Technology, Research and Management
- Vol. 13 (2) , 48-59
HPTLC Driven Analytical Approaches for Antidiabetic Pharmaceuticals: A Detailed Review
Background: Diabetes mellitus is a chronic disease affecting a large number of populations across the world, and it also requires management using anti-diabetic drugs. Various drugs such as metformin, vildagliptin, saxagliptin, sitagliptin, rosiglitazone, glipizide, and their combinations are commonly used for the treatment. Numerous pharmaceutical formulations are available in the market in combination forms as well. In order to ensure the quality, appropriate dosage, and regulatory compliance of these formulations, accurate and reliable analytical methods are essential. Purpose: This review will provide comprehensive insight into HPTLC-based analytical approaches used for qualitative and quantitative analysis of anti-diabetic drugs in various pharmaceutical formulations. Methods: This review critically summarizes the literature reporting HPTLC methods developed for the analysis of anti-diabetic drugs. Key aspects such as HPTLC method development, mobile phase and stationary phase selection, detection methods, and optimization strategies are discussed. Method validation parameters such as robustness, sensitivity, reproducibility, and accuracy are mentioned. Results: The study demonstrated that the HPTLC method is a reliable and efficient analytical technique for the evaluation of anti-diabetic drugs due to its low cost, high reproducibility, minimal solvent consumption, and ability to analyze multiple samples simultaneously. For routine quality control and research applications, validated HPTLC methods have shown satisfactory performance. Conclusion: HPTLC represents itself as a valuable tool for the qualitative as well as quantitative assessment of anti-diabetic formulations. This detailed review provides guidance for researchers as well as analysts in selecting and optimizing appropriate HPTLC protocols for research and quality control purposes. It also highlights the potential for further advancements in HPTLC-based drug analysis.
- 13 February 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70249
Structural Exploration of Pyrazine‐1,2,3‐Triazole Hybrids as Selective Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to gradual deterioration of cognitive functions. Cholinesterase enzymes play a critical role in regulating acetylcholine levels in the brain, and their dysfunction leads to impaired cholinergic neurotransmission, which is a primary hallmark of AD and contributes significantly to the cognitive decline and dementia. Here, a series of pyrazine‐1,2,3‐triazole molecular hybrids incorporating a trifluoromethyl (‐CF 3 ) group were synthesized ( 8a–o ). Synthesized compounds were then evaluated in vitro for cytotoxicity and cholinesterase inhibitory activities. All synthesized compounds were found to be nontoxic toward BV‐2 cells in the cytotoxicity screening. The in vitro inhibition assays revealed that these derivatives exhibited greater inhibitory potency against acetylcholinesterase (AChE) than butyrylcholinesterase (BuChE). Among them, compound 8h demonstrated the most potent AChE inhibition compared to BuChE ( AChE, IC 50 = 5.43 µM; BuChE, IC 50 = 127.12 µM ). The most active compound 8h was further subjected to molecular docking and dynamic simulation (100 ns) to investigate its binding affinity, thermodynamic behavior, and stability within the active site of cholinesterase enzymes. Overall, the findings suggested that the synthesized compounds represent promising drug candidates as selective acetylcholinesterase inhibitors for the treatment of AD.
- 13 February 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70249
Structural Exploration of Pyrazine‐1,2,3‐Triazole Hybrids as Selective Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to gradual deterioration of cognitive functions. Cholinesterase enzymes play a critical role in regulating acetylcholine levels in the brain, and their dysfunction leads to impaired cholinergic neurotransmission, which is a primary hallmark of AD and contributes significantly to the cognitive decline and dementia. Here, a series of pyrazine‐1,2,3‐triazole molecular hybrids incorporating a trifluoromethyl (‐CF 3 ) group were synthesized ( 8a–o ). Synthesized compounds were then evaluated in vitro for cytotoxicity and cholinesterase inhibitory activities. All synthesized compounds were found to be nontoxic toward BV‐2 cells in the cytotoxicity screening. The in vitro inhibition assays revealed that these derivatives exhibited greater inhibitory potency against acetylcholinesterase (AChE) than butyrylcholinesterase (BuChE). Among them, compound 8h demonstrated the most potent AChE inhibition compared to BuChE ( AChE, IC 50 = 5.43 µM; BuChE, IC 50 = 127.12 µM ). The most active compound 8h was further subjected to molecular docking and dynamic simulation (100 ns) to investigate its binding affinity, thermodynamic behavior, and stability within the active site of cholinesterase enzymes. Overall, the findings suggested that the synthesized compounds represent promising drug candidates as selective acetylcholinesterase inhibitors for the treatment of AD.
- 11 January 2026
- Published by Elsevier in Microchemical Journal
- Vol. 221
Validated analytical protocols for analysis of loteprednol etabonate: Exploration to nanosuspension formulation and characterization
- 11 January 2026
- Published by Elsevier in Microchemical Journal
- Vol. 221
Validated analytical protocols for analysis of loteprednol etabonate: Exploration to nanosuspension formulation and characterization
- 10 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118224
Benzoxaboroles in medicinal chemistry: A structure-guided perspective on next-generation therapeutics
- 10 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118224
Benzoxaboroles in medicinal chemistry: A structure-guided perspective on next-generation therapeutics
- 2 August 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (8) , 3857-3864
Fabrication of Dolutegravir Sodium Cocrystals: Characterization, In vitro, In vivo Evaluation of Cocrystal Suspension Formulation
The objective of this research was to increase the solubility of Antiretroviral Dolutegravir sodium (DGS), drug by utilizing co-crystallization technique as well formulating Suspension of Dolutegravir sodium cocrystals to enhance the therapeutic effectiveness. Dolutegravir Sodium (DGS) and Salicylic acid cocrystal were created in 1:1 ratio utilizing ethanol as solvent-by-solvent evaporation technique. Developed Cocrystals of Dolutegravir Sodium (DGS) and Salicylic acid assessed for preliminary characterization by utilizing PXRD, DCS, FTIR and SEM. Suspension that contained DGS cocrystals characterized for Dissolution rate, Drug content, Flow rate and Stability study. The findings indicated that the prepared suspension exhibited satisfactory characteristics and remained stable under the testing conditions. In vivo results demonstrate that the tested formulation exhibit quicker absorption compared to the formulation used as control. Hence it can be inferred that Suspension composed of Dolutegravir sodium (DGS) cocrystals shows improved therapeutic performance.
- 2 August 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (8) , 3857-3864
Fabrication of Dolutegravir Sodium Cocrystals: Characterization, In vitro, In vivo Evaluation of Cocrystal Suspension Formulation
The objective of this research was to increase the solubility of Antiretroviral Dolutegravir sodium (DGS), drug by utilizing co-crystallization technique as well formulating Suspension of Dolutegravir sodium cocrystals to enhance the therapeutic effectiveness. Dolutegravir Sodium (DGS) and Salicylic acid cocrystal were created in 1:1 ratio utilizing ethanol as solvent-by-solvent evaporation technique. Developed Cocrystals of Dolutegravir Sodium (DGS) and Salicylic acid assessed for preliminary characterization by utilizing PXRD, DCS, FTIR and SEM. Suspension that contained DGS cocrystals characterized for Dissolution rate, Drug content, Flow rate and Stability study. The findings indicated that the prepared suspension exhibited satisfactory characteristics and remained stable under the testing conditions. In vivo results demonstrate that the tested formulation exhibit quicker absorption compared to the formulation used as control. Hence it can be inferred that Suspension composed of Dolutegravir sodium (DGS) cocrystals shows improved therapeutic performance.
- 30 May 2025
- Published by Springer Nature in Journal of Applied Spectroscopy
- Vol. 92 (2) , 446-454
Green Analytical Chemistry Compliant UV-Visible Spectrophotometry Estimations for Sunitinib Malate
- 30 May 2025
- Published by Springer Nature in Journal of Applied Spectroscopy
- Vol. 92 (2) , 446-454
Green Analytical Chemistry Compliant UV-Visible Spectrophotometry Estimations for Sunitinib Malate
- 25 April 2025
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 30 (3) , 261-275
Combined analytical, eco-friendly, and validated stability indicating method development of tavaborole with the study of its degradants via LC–MS
- 25 April 2025
- Published by Springer Nature in Accreditation and Quality Assurance
- Vol. 30 (3) , 261-275
Combined analytical, eco-friendly, and validated stability indicating method development of tavaborole with the study of its degradants via LC–MS
- 7 January 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (1) , 1-14
Advanced Normal-Phase HPTLC Profiling of Eltrombopag Olamine with Automated Development and Box-Behnken Optimizations
- 7 January 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (1) , 1-14
Advanced Normal-Phase HPTLC Profiling of Eltrombopag Olamine with Automated Development and Box-Behnken Optimizations
- 15 October 2024
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 83 (1) , 33-44
An investigative review for pharmaceutical analysis of angiotensin receptor blockers: Olmesartan medoxomil
- 15 October 2024
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 83 (1) , 33-44
An investigative review for pharmaceutical analysis of angiotensin receptor blockers: Olmesartan medoxomil
- 14 September 2024
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 325, 125122
Eco-friendly hydrotropic spectrophotometric analysis of ranolazine hydrochloride
- 14 September 2024
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 325, 125122
Eco-friendly hydrotropic spectrophotometric analysis of ranolazine hydrochloride